Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe immune cells behind rare anemia

NCT ID NCT02158195

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how certain immune cells, called T cells, behave in people with autoimmune hemolytic anemia, a condition where the body attacks its own red blood cells. Researchers compared blood samples from 27 patients and healthy volunteers to understand the disease better. The goal was to learn more about what goes wrong in the immune system, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could improve understanding of how the immune system attacks red blood cells in autoimmune hemolytic anemia, potentially pointing toward new treatment targets.
What could go wrong
This is an observational study with only 27 participants, so findings may not apply to all patients. It does not test a new treatment, so direct benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

27 people

The number who actually took part.

Started

Jul 2013

Finished

Dec 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with warm primary or secondary Autoimmune Hemolytic Anemia

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with primary warm Autoimmune Hemolytic Anemia (wAIHA) * Secondary AHAI (infections, hematological diseases, systemic diseases) * Naive of treatment for hemolytic anemia or in relapse * Older than 16 * Able to understand written and spoken French * who have provided written informed consent * INCLUSION CRITERIA for CONTROLS * Persons without auto-immune disease, cancer or active infection. * Older than 16 * Able to understand written and spoken French * who have provided written informed consent Exclusion Criteria: * Cold agglutinin disease * Pregnancy * Persons without national health insurance Exclusion Criteria for Controls: * Subjects treated with corticosteroids or immunosuppressants * Pregnancy * Persons without national health insurance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune hemolytic anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia autoimmune hemolytic anemia, warm type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune hemolytic anemia

Contacts and locations

Locations

  • CH de Chalon-sur-Saône

    Chalon-sur-Saône, 71100, France

  • CH de METZ

    Metz, 57000, France

  • CH de Mâcon

    Mâcon, 71018, France

  • CHU de Besançon

    Besançon, 25030, France

  • CHU de DIJON

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.